On Wednesday, PMC-Sierra Inc (NASDAQ:PMCS)’s shares showed no change to $7.93.
PMC-Sierra Inc (PMCS) declared the appointment of Edward Sharp as chief strategy and technology officer. He reports to Greg Lang, PMC president and chief executive officer.
In this role, Sharp is responsible for leading PMC’s worldwide strategy and technology efforts, mapping emerging technologies into solutions that shape how the world consumes data. The exploding growth of big data puts PMC in a strong position to capitalize on the convergence of storage and networking, and to guide future industry-wide developments by participating in standards organizations.
Prior to joining PMC, Mr. Sharp was vice president of NetApp’s Emerging Products Group. He served in a number of roles of increasing scope in NetApp’s marketing, sales and product organizations from 1998 to 2014. Before joining NetApp, Mr. Sharp held positions at McKinsey & Company in the United States and the United Kingdom. He holds a Master of Science in Electrical Engineering from Stanford University and a Bachelor of Arts in Engineering, Economics and Administration from Oxford University.
PMC-Sierra, Inc. designs, develops, markets, and supports semiconductor solutions for communications network infrastructure equipment worldwide. Its semiconductor devices enable networking equipment primarily in three markets, counting storage, optical, and mobile networks.
Organovo Holdings Inc (NYSEMKT:ONVO)’s shares dropped -5.58% to $3.89.
Organovo Holdings Inc (ONVO) stated its financial results for the fiscal year ended March 31, 2015. The Company also stated its total contract bookings for the exVive3D™ Human Liver Tissue.
The exVive3D Human Liver Tissue is a combination product and service offered by the Company to pharmaceutical industry customers for use mainly in preclinical safety testing. From April 1, 2014 through the date of this release, the Company has recorded total contract bookings for its commercial liver tissue product of about $1.94 million, which comprises $0.29 million in revenue recognized as of March 31, 2015. The customers who have contracted to utilize the exVive3D Human Liver Tissue comprise multiple top 25 global pharma companies, additional public pharmaceutical companies from small to large cap and private venture-backed companies. The Company has had multiple customers sign a second contract, representing repeat business for its liver tissue product. The Company has signed liver service contracts with customers in the United States, Europe and Asia. These stated total contract bookings do not comprise the Company’s contract bookings associated with its research and development activities not involving the exVive3D Human Liver Tissue.
Organovo Holdings, Inc., a development-stage company, focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs.
At the end of Wednesday’s trade, AstraZeneca plc (ADR) (NYSE:AZN)‘s shares surged 0.07% to $67.89.
AstraZeneca plc (ADR) (AZN) presented at the European League Against Rheumatism Annual Congress (EULAR 2015) in Rome, results of its Phase III double-blind, multicenter, placebo-controlled trial CRYSTAL, investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination with the xanthine oxidase inhibitor (XOI) febuxostat. The results demonstrated that lesinurad in combination with febuxostat lowered serum uric acid (sUA) levels and reduced tophus area to a greater extent than febuxostat alone. Lesinurad is an investigational agent that inhibits the uric acid transporter URAT1 in the kidney, increasing uric acid excretion and thereby lowering sUA. Lesinurad works in combination with febuxostat to provide a dual mechanism of action which enhances excretion and decreases production of uric acid.
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its principal products comprise Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders.
Clean Energy Fuels Corp (NASDAQ:CLNE), ended its Wednesday’s trading session with -5.90% loss, and closed at $6.38.
Clean Energy Fuels Corp. (CLNE) declared it will release financial results for the second quarter of 2015 on Wednesday, August 5, 2015 after market close, followed by an investor conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific). President and Chief Executive Officer of Clean Energy Andrew J. Littlefair and Chief Financial Officer Bob Vreeland will host the call.
Clean Energy Fuels Corp. provides natural gas as an alternative fuel for vehicle fleets in the United States and Canada. It designs, builds, operates, and maintains fueling stations; and supplies compressed natural gas (CNG) fuel for light, medium, and heavy-duty vehicles, in addition to liquefied natural gas (LNG) fuel for medium and heavy-duty vehicles.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
